Abstract 1845P
Background
Lung cancer affects older and very older adults and is the leading cause of death by cancer. Comprehensive Geriatric Assessment (CGA) is recommended before and during cancer treatment to guide therapy management in this population.
Methods
This study was conducted between September 2015 and January 2019 at Marseille University Hospital (AP-HM). During this period, all consecutive older outpatients referred for a CGA before initiation of lung cancer treatment were enrolled. Our objectives were to compare overall survival (OS), lung cancer management and geriatric profile of patients over 80 years versus younger patients.
Results
A total of 228 patients were recruited. The median age was 78.7 ± 5 years. In our study sample, 94 patients were octogenarians (41.2%), 36.2% were diagnosed with stage IV neoplasm and the most common treatment was chemotherapy (43.6%). The multivariate analysis highlighted that octogenarian patients were more likely than younger patients to be treated by targeted therapy (OR 9.8; 95% CI [1.0-92.9]) or best supportive care (OR 4.7; 95% CI [0.9-24.4]) and that handgrip strength was the most commonly impaired geriatric domain (OR 2.3; 95% CI [1.3-4.3]) in this population. OS was similar in both age group (HR=0.9; 95% CI [0.7-1.5]).
Conclusions
In our study, octogenarians have a survival rate comparable to that of the younger patients, irrespective of lung cancer treatments and tumor stages. Measurement of muscle strength in CGA could be very useful in a clinical setting to help improve the management of very older patients treated for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A-L. Couderc: Honoraria (self): Nutricia; BMS; Ferring. P. Tomasini: Honoraria (self): Roche; Astra-Zeneca; MSD; BMS; Takeda. F. Barlesi: Honoraria (self), Honoraria (institution): astra-Zeneca; Bayer; BMS; Boehringer-Ingelheim; Eli Lilly Oncology; F. Hoffmann-La Roche Ltd; Novartis; Merck; MSD; Pierre Fabre; Pfizer; Takeda; Honoraria (institution): Abbvie; ACEA; Amgen; Genentech; Ipsen; Ignyta; Innate Pharma; Loxo; Medimmune; Sanofi-Aventis. L. Greillier: Honoraria (self): Abbvie; BMS; Boehringer Ingelheim; Astra Zeneca; Roche; Novartis; MSD; Pfizer. All other authors have declared no conflicts of interest.